If a company has a priced round and ARR, evaluation is more deterministic — so growth-stage funds should be easier to serve, not harder.
The argument is intuitive: early-stage diligence is hard because almost nothing is verifiable. The founder may or may not have the background they claim. The market may or may not be real. The product may or may not work. Our product's core value is synthesizing qualitative signals from unstructured sources when hard data is absent.
At growth stage — Series B, C, and beyond — a company has operated for several years. It has revenue, retention data, a track record of execution, a team that has been tested. It has raised a priced round, which means institutional investors have already done a version of the work. The hypothesis is that this data-richness makes the evaluation workflow more tractable for a tool like ours, and that growth-stage funds represent a natural adjacent market.
Is the hypothesis correct that "more deterministic evaluation" makes growth-stage VC a good near-term TAM expansion? Or does determinism in the data change the product problem in ways that break the fit?
Many Series A investments — particularly at the $5M–$15M check size into companies with $500K–$3M ARR — are still primarily thesis-driven, team-driven decisions. The revenue exists, but it's not yet the dominant signal. The fund is still asking: is this the right founder, is this the right market, do the early signals of product-market fit hold up under scrutiny? That's the question our product answers, and it applies even when there is some ARR on the table.
A meaningful portion of Series A fund activity, particularly at the pre-institutional end, behaves more like a late seed round than a growth investment. Those funds are already in our target addressable market or just beyond its edge.
Even at Series B, investors care about the executive team — whether the founding team has scaled before, whether key hires have the right background, whether there are gaps on the leadership bench. Founder and team research is a durable component of the diligence workflow at every stage. Our synthesis capability on people remains relevant well past the early stage.
There are roughly 2,000–4,000 active growth-stage VC funds globally (Series B through pre-IPO), many of them running more intensive, higher-frequency deal processes than early-stage funds. The ARPU multiplier would be materially higher — these are larger teams with larger budgets and higher deal volume. The excluded segments section of the pricing model partially captures this via the "multi-stage & larger VC" category (4,000 firms at 2.5× ARPU multiplier).
The flaw in the hypothesis is conflating two different things: evaluability and evaluability with our product. Yes, a company with $5M ARR and two priced rounds can be evaluated with more precision. But that precision comes from financial analysis — cohort analysis, revenue quality assessment, net revenue retention, unit economics, burn multiple — not from qualitative signal synthesis. The workflow shifts from "research this person and market" to "model this business." Those are different products.
Our edge is highest where data is scarce. That's where manual research is slowest, where error rates from human judgment are highest, and where the cost of getting it wrong is most asymmetric. At growth stage, the hard data exists. The value of synthesising qualitative signals from public sources shrinks as structured financial data becomes the primary input. We would be solving a problem that already has better-equipped tools pointed at it.
PitchBook has the financials. FactSet has the comparables. Refinitiv has the transaction data. Bloomberg has the macro context. These tools were built for this exact workflow, at this exact stage, with institutional data coverage that took years to build. We cannot compete on the financial analysis dimension of growth-stage diligence without a data moat we don't have and aren't building toward. Our moat is agentic synthesis of unstructured qualitative signals — a strength that declines in importance as stage increases.
Early-stage diligence is typically owned by analysts and associates who move fast, try new tools, and have low procurement friction. Growth-stage diligence — particularly at Series B+ — is often run or overseen by operating partners, deal leads, or specialist DD firms. These buyers have established vendor relationships, compliance requirements, and are accustomed to enterprise contracts with SLAs. The self-serve, token-consumption model that makes us accessible to a seed fund is mismatched to how growth-stage funds procure.
A priced round means someone else already paid for diligence — it doesn't mean the diligence was right, or that it covered the dimensions a new investor cares about. Growth-stage investors still uncover misrepresentation, market misjudgments, and team fragility. But the primary tools for catching those issues at growth stage are reference checks, financial audits, customer interviews, and legal review — not web research synthesis. The qualitative research surface area shrinks as companies mature.
The hypothesis assumes that "more evaluable" means "better fit for our product." The reverse is closer to true: the harder the qualitative synthesis problem, the more value we deliver. Our product is at its best when hard data is absent and human judgment error is highest — which is precisely the early-stage condition.
How well does the product fit the diligence workflow at each funding stage?
| Stage | Typical check size | Primary diligence driver | Product fit | Notes |
|---|---|---|---|---|
| Pre-Seed | $250K–$1M | Founder, market thesis, early signal | Strong | Core ICP. Almost entirely qualitative. Our product is purpose-built for this. |
| Seed | $1M–$4M | Founder, team, market, early traction | Strong | Core ICP. Still largely qualitative even where early revenue exists. |
| Series A | $5M–$20M | Mixed — team + early metrics + market | Partial | Genuine overlap zone. Early-thesis funds behave like seed. Data-driven funds start shifting toward financial analysis. Worth capturing; already partially in our addressable market. |
| Series B | $20M–$60M | Revenue quality, retention, unit economics | Weak | Financial analysis dominates. Qualitative synthesis becomes secondary. Different buyer, different tool set, PitchBook/FactSet territory. |
| Series C+ | $60M+ | Financial model, QoE, market position | Not applicable | Specialist financial DD, legal review, audited financials. Entirely different product category. Our value proposition does not apply. |
The near-term expansion story is better told through firm type (multi-stage funds, PE, family offices, corporate VC) than through stage. Those firm types already carry higher ARPU multipliers in the excluded segments model and are more honest about the product extension required. Adding "growth-stage funds" as a TAM line implies the product already fits — which it doesn't cleanly, beyond Series A.
Many Series A-focused funds behave like late-seed investors and are already embedded in the 6,000–8,000 active early-stage fund count. Adding them as a separate segment would double-count. The more accurate framing is that our early-stage TAM already includes the Series A funds where the diligence workflow is still qualitatively driven.
If we build structured financial analysis capability on top of the qualitative synthesis engine — connecting to financial data providers, modelling unit economics, running scenario analysis — then Series B diligence becomes a genuine expansion. But that is a second product built on top of the first, not an extension of the current workflow. It requires a different data strategy, a different integration surface, and likely a different pricing model. Worth flagging as a future direction, not a near-term one.
Target early-stage VC (Pre-Seed through Series A, qualitative-thesis-driven subset) as the beachhead. Capture growth-stage as a future expansion narrative contingent on building structured financial analysis capability. Do not include Series B+ in TAM calculations until the product scope expands to cover financial DD workflows.